List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4660243/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. Annals of Internal Medicine, 2022, 175, 36-45.	2.0	25
2	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. MDM Policy and Practice, 2021, 6, 238146832098497.	0.5	4
3	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. European Journal of Cancer, 2020, 127, 224-235.	1.3	101
4	Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Journal of Medical Screening, 2019, 26, 76-83.	1.1	19
5	Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut, 2019, 68, 1232-1244.	6.1	113
6	Flexible Sigmoidoscopy and CT Colonography Screening: Patients' Experience with and Factors for Undergoing Screening—Insight from the Proteus Colon Trial. Radiology, 2018, 286, 873-883.	3.6	17
7	Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening. Gastroenterology, 2018, 155, 1059-1068.e2.	0.6	8
8	Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. Gut, 2017, 66, gutjnl-2016-311906.	6.1	59
9	Distribution of colorectal polyps: Implications for screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 481-488.	1.0	8
10	Comparing CT colonography and flexible sigmoidoscopy: a randomised trial within a population-based screening programme. Gut, 2017, 66, 1434-1440.	6.1	26
11	Early detection versus prevention in colorectal cancer screening: Methods estimates and public health implications. Cancer, 2017, 123, 4767-4769.	2.0	5
12	Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries. Health Policy, 2017, 121, 1072-1078.	1.4	9
13	Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ: British Medical Journal, 2017, 356, i6673.	2.4	100
14	Absence of socioeconomic inequalities in access to good-quality breast cancer treatment within a population-wide screening programme in Turin (Italy). European Journal of Cancer Prevention, 2016, 25, 538-546.	0.6	6
15	Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: A systematic review. International Journal of Cancer, 2016, 139, 554-573.	2.3	14
16	The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. European Journal of Public Health, 2016, 26, 83-89.	0.1	21
17	European Code against Cancer, 4th Edition: Cancer screening. Cancer Epidemiology, 2015, 39, S139-S152.	0.8	64
18	European Code against Cancer 4th Edition: Process of reviewing the scientific evidence and revising the recommendations. Cancer Epidemiology, 2015, 39, S11-S19.	0.8	23

#	Article	IF	CITATIONS
19	Optimising colorectal cancer screening acceptance: a review. Gut, 2015, 64, 1158-1177.	6.1	92
20	Invitation strategies for colorectal cancer screening programmes: The impact of an advance notification letter. Preventive Medicine, 2015, 73, 106-111.	1.6	26
21	Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, .	3.0	61
22	Assessing Generalizability of the Findings of Sigmoidoscopy Screening Trials: The Case of SCORE Trial. Journal of the National Cancer Institute, 2015, 107, 385.	3.0	4
23	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 22-31.	4.5	181
24	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
25	Colorectal cancer screening of immigrants to Italy. Figures from the 2013 National Survey. Preventive Medicine, 2015, 81, 132-137.	1.6	16
26	Histological features of advanced colorectal adenomas detected by endoscopy and fecal immunochemical test. Endoscopy, 2015, 47, 903-909.	1.0	7
27	Warunki skutecznej realizacji programów populacyjnych badań przesiewowych w kierunku nowotworów. Nowotwory, 2015, 64, 511-517.	0.1	1
28	Computer-Aided Detection for Computed Tomographic Colonography Screening. Investigative Radiology, 2014, 49, 173-182.	3.5	19
29	Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer. Obstetrical and Gynecological Survey, 2014, 69, 472-473.	0.2	1
30	A comparison of different strategies used to invite subjects with a positive faecal occult blood test to a colonoscopy assessment. A randomised controlled trial in population-based screening programmes. Preventive Medicine, 2014, 65, 70-76.	1.6	10
31	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	6.3	1,282
32	Lifetime growth and risk of testicular cancer. International Journal of Cancer, 2014, 135, 695-701.	2.3	16
33	International variation in management of screen-detected ductal carcinoma in situ of the breast. European Journal of Cancer, 2014, 50, 2695-2704.	1.3	32
34	Population screening for colorectal cancer by flexible sigmoidoscopy or CT colonography: study protocol for a multicenter randomized trial. Trials, 2014, 15, 97.	0.7	22
35	HPV-based screening for prevention of invasive cervical cancer – Authors' reply. Lancet, The, 2014, 383, 1295.	6.3	10
36	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: A randomised trial. Digestive and Liver Disease, 2014, 46, 803-807.	0.4	14

#	Article	IF	CITATIONS
37	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infectious Diseases, 2013, 13, 238.	1.3	19
38	Compliance with clinical practice guidelines for breast cancer treatment: a population-based study of quality-of-care indicators in Italy. BMC Health Services Research, 2013, 13, 28.	0.9	23
39	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2013, 14, 168-176.	5.1	139
40	CT Colonography: Preliminary Assessment of a Double-Read Paradigm That Uses Computer-aided Detection as the First Reader. Radiology, 2013, 268, 743-751.	3.6	19
41	Offering people a choice for colorectal cancer screening. Gut, 2013, 62, 735-740.	6.1	50
42	Breast Cancer Mortality in Mammographic Screening in Europe: A Review of Incidence-Based Mortality Studies. Journal of Medical Screening, 2012, 19, 33-41.	1.1	152
43	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. American Journal of Clinical Pathology, 2012, 138, 65-71.	0.4	11
44	Population Based Cancer Screening Programmes as a Teachable Moment for Primary Prevention Interventions. A Review of the Literature. Frontiers in Oncology, 2012, 2, 45.	1.3	48
45	Is the Breast Cancer Mortality Decrease in Sweden Due to Screening or Treatment? Not the Right Question. Journal of the National Cancer Institute, 2012, 104, 1040-1041.	3.0	3
46	The impact of different communication and organizational strategies on mammography screening uptake in women aged 40-45 years. European Journal of Public Health, 2012, 22, 413-418.	0.1	16
47	High Rate of Advanced Adenoma Detection in 4 Rounds of Colorectal Cancer Screening With the Fecal Immunochemical Test. Clinical Gastroenterology and Hepatology, 2012, 10, 633-638.	2.4	103
48	Determinants of successful implementation of population-based cancer screening programmes. European Journal of Cancer, 2012, 48, 743-748.	1.3	56
49	Mammographic Screening Programmes in Europe: Organization, Coverage and Participation. Journal of Medical Screening, 2012, 19, 72-82.	1.1	142
50	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine, 2011, 29, 1270-1277.	1.7	24
51	HPV16 and HPV18 genotyping in cervical cancer screening. Lancet Oncology, The, 2011, 12, 831-832.	5.1	7
52	Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiology, 2011, 35, e18-e24.	0.8	12
53	Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled Trial–SCORE. Journal of the National Cancer Institute, 2011, 103, 1310-1322. 	3.0	539
54	Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. Journal of Medical Screening, 2011, 18, 128-134.	1.1	73

4

#	Article	IF	CITATIONS
55	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 379-380.	1.0	О
56	Virtual microscopy for histology quality assurance of screen-detected polyps. Journal of Clinical Pathology, 2010, 63, 916-920.	1.0	19
57	Comparing Different Strategies for Colorectal Cancer Screening in Italy: Predictors of Patients' Participation. American Journal of Gastroenterology, 2010, 105, 188-198.	0.2	64
58	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. Epidemics, 2010, 2, 21-28.	1.5	27
59	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology, The, 2010, 11, 249-257.	5.1	797
60	Cervical screening according to age and HPV status. BMJ: British Medical Journal, 2009, 339, b3005-b3005.	2.4	8
61	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer, 2009, 45, 2714-2721.	1.3	44
62	Improving the quality of communication in organised cervical cancer screening programmes. Patient Education and Counseling, 2008, 72, 130-136.	1.0	23
63	A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. Journal of Clinical Epidemiology, 2008, 61, 373-379.	2.4	71
64	Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. European Journal of Cancer, 2008, 44, 858-865.	1.3	10
65	Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: Results from a long-term follow-up study of Italian patients. European Journal of Cancer, 2008, 44, 1275-1281.	1.3	42
66	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2008, 9, 937-945.	5.1	170
67	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. Journal of the National Cancer Institute, 2008, 100, 492-501.	3.0	259
68	Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 28.	2.4	224
69	Re: Breast Cancer Incidence, 1980-2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status. Journal of the National Cancer Institute, 2007, 99, 1817-1818.	3.0	26
70	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. European Journal of Cancer, 2007, 43, 476-480.	1.3	65
71	Accessibility as a major determinant of radiotherapy underutilization: A population based study. Health Policy, 2007, 80, 483-491.	1.4	41
72	HPV testing for primary cervical cancer screening. Lancet, The, 2007, 370, 1740-1742.	6.3	28

#	Article	IF	CITATIONS
73	Comparing Attendance and Detection Rate of Colonoscopy With Sigmoidoscopy and FIT for Colorectal Cancer Screening. Gastroenterology, 2007, 132, 2304-2312.	0.6	241
74	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. International Journal of Cancer, 2007, 121, 2729-2734.	2.3	10
75	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecologic Oncology, 2007, 107, S230-S232.	0.6	17
76	Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Research, 2006, 8, R68.	2.2	79
77	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. Journal of the National Cancer Institute, 2006, 98, 765-774.	3.0	275
78	Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncology, The, 2006, 7, 547-555.	5.1	202
79	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. Journal of Clinical Virology, 2006, 36, 126-132.	1.6	19
80	History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. International Journal of Colorectal Disease, 2006, 21, 105-113.	1.0	7
81	Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centres. Journal of Medical Screening, 2005, 12, 43-49.	1.1	20
82	Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. Journal of the National Cancer Institute, 2005, 97, 347-357.	3.0	178
83	Re: Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials. Journal of the National Cancer Institute, 2005, 97, 1853-1854.	3.0	4
84	What information do breast cancer screening programmes provide to Italian women?. European Journal of Public Health, 2005, 15, 66-69.	0.1	13
85	Prevalence of human papillomavirus infection in women in Turin, Italy. European Journal of Cancer, 2005, 41, 297-305.	1.3	94
86	Early diagnosis, not differential treatment, explains better survival in service screening. European Journal of Cancer, 2005, 41, 2728-2734.	1.3	42
87	Predicting Proximal Advanced Neoplasms at Screening Sigmoidoscopy. Diseases of the Colon and Rectum, 2004, 47, 1331-1340.	0.7	17
88	Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"SCORE. Journal of the National Cancer Institute, 2002, 94, 1763-1772.	3.0	206
89	Impact of the AutoPap (currently focalpoint) primary screening system location guide use on interpretation time and diagnosis. Cancer, 2002, 99, 83-88.	2.0	12
90	Predictors of Smoking Cessation Following Physician' Counseling. Preventive Medicine, 1998, 27, 412-421.	1.6	61

#	Article	IF	CITATIONS
91	ADJUSTING FOR NON-COMPLIANCE AND CONTAMINATION IN RANDOMIZED CLINICAL TRIALS. Statistics in Medicine, 1997, 16, 1017-1029.	0.8	277
92	Screening for Colorectal Cancer by Once Only Sigmoidoscopy: A Feasibility Study in Turin, Italy. Journal of Medical Screening, 1996, 3, 72-78.	1.1	44
93	The differential diagnosis of primary lung cancer: Inter-observer agreement and contribution of specific diagnostic procedures. Journal of Clinical Epidemiology, 1992, 45, 827-833.	2.4	5
94	Inter-observer and intra-observer variability of mammogram interpretation: a field study. European Journal of Cancer, 1992, 28, 1054-1058.	1.3	53
95	A randomized trial of smoking cessation interventions in general practice in Italy. Cancer Causes and Control, 1991, 2, 239-246.	0.8	77
96	Who Has Pap Tests?: Variables Associated with the Use of Pap Tests in Absence of Screening Programmes. International Journal of Epidemiology, 1991, 20, 349-353.	0.9	40
97	Exposure of nonsmoking women to environmental tobacco smoke: a 10-country collaborative study. Cancer Causes and Control, 1990, 1, 243-252.	0.8	127